← Alle mensen

RA

Ross A Soo

7 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Eerstelijns Lorlatinib Versus Crizotinib in Asian Patiënten met Gevorderd ALK-Positive NSCLC: Five-Year Outcomes From...

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-07

ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab...

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 november 2024

Lorlatinib versus crizotinib bij ALK-positief NSCLC: CROWN vijfjaars

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 oktober 2024

Tiragolumab plus atezolizumab plus chemo bij uitgebreid SCLC: SKYSCRAPER-02 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 januari 2024

CZS-uitkomsten van lazertinib versus gefitinib bij EGFR-gemuteerd NSCLC: LASER301 analyse

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-12

Lazertinib versus gefitinib bij EGFR-gemuteerd NSCLC: LASER301 update

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-10

Lazertinib versus gefitinib als eerstelijns bij EGFR-gemuteerd NSCLC: LASER301 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 september 2023